2,3-二氢-1,4-苯并二恶烷-6-羰酰氯 | 6761-70-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 2,3-二氢-1,4-苯并二恶烷-6-羰酰氯
• 中文别名: 1,4-苯并二噁烯-6-羰基氯化物,2,3-二氢；1,4-苯并二氧杂六环-6-甲酰氯；6-氯-2,3-二氨基吡啶；苯并二氧六环-6-甲酰氯
• 英文名称: 2,3-dihydro-1,4-benzodioxine-6-carbonyl chloride
• 英文别名: 2,3-dihydrobenzo[b][1,4]dioxine-6-carbonyl chloride；2,3-dihydrobenzo[b][1,4]dioxin-6-formyl chloride
• CAS: 6761-70-2
• 化学式: C₉H₇ClO₃
• mdl: MFCD02681889
• 分子量: 198.606
• InChiKey: QECXDXFCJKMZLA-UHFFFAOYSA-N

物化性质

• 熔点：
  100 °C
• 沸点：
  301.7±41.0 °C(Predicted)
• 密度：
  1.371±0.06 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R20/22,R34,R29,R14
• 海关编码：
  2932999099

SDS

Name:	2 3-Dihydro-1 4-benzodioxine-6-carbonyl chloride 97% Material Safety Data Sheet
Synonym:	Benzodioxan-6-carbonylchlorid
CAS:	6761-70-2

Section 1 - Chemical Product MSDS Name:2 3-Dihydro-1 4-benzodioxine-6-carbonyl chloride 97% Material Safety Data Sheet
Synonym:Benzodioxan-6-carbonylchlorid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6761-70-2	2,3-Dihydro-1,4-benzodioxine-6-carbony	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6761-70-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 102 - 104 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H7ClO3
Molecular Weight: 199

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6761-70-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,3-Dihydro-1,4-benzodioxine-6-carbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 6761-70-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6761-70-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6761-70-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二氢-1,4-苯并二恶烷-6-羰酰氯 在 N-[（1R，2R）-2-氨基-1,2-二苯乙基]-1,1,1-三氟甲烷磺酰胺 、 N-甲基咪唑 、 盐酸 、 甲酸 、 (p-cymene)ruthenium(II) chloride 、 palladium on activated charcoal 、 5,5-dibromohydantoin 、 水 、 氢气 、 碳酸氢钠 、 二乙胺 、 N,N-二异丙基乙胺 、 红铝 、 sodium hydroxide 、 magnesium chloride 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 异丙醇 、 甲苯 、 乙腈 为溶剂， 85.0 ℃ 、101.33 kPa 条件下， 反应 78.37h， 生成 依利格鲁司特
  参考文献：
  名称：

  依鲁司他中间体及其制备方法

  摘要：

  本发明涉及依鲁司他中间体及其制备方法。本发明提供了一系列中间体化合物，其可以用于制备依鲁司他，还提供了这些中间体的制备方法，本发明的方法通过原料和过渡金属催化剂在一定条件下进行不对称氢化反应，然后经过一系列反应，能够制备得到依鲁司他。本发明的方法反应条件相对简单可控，易于工业化生产。

  公开号：

  CN111217791A
• 作为产物：
  描述：

  1,4-苯并二恶烷-6-甲醛 在 potassium permanganate 、 氯化亚砜 作用下， 生成 2,3-二氢-1,4-苯并二恶烷-6-羰酰氯
  参考文献：
  名称：

  Structure–activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs

  摘要：

  Structure-activity relationships on two novel potent cognition enhancing drugs, unifiram (DM232, 1) and sunifiram (DM235, 2), are reported. Although none of the compounds synthesised reached the potency of the parent drugs, some fairly active compounds have been identified that may represent new leads to develop other cognition enhancing drugs. An interesting result of this research is the identification of two compounds (13 and 14) that are endowed with amnesing activity (the opposite of the activity of the original molecules) and are nearly equipotent to scopolamine. Moreover, two compounds of the series (5 and 6) were found endowed with analgesic activity on a rat model of neuropathic pain at the dose of 1 mg/kg. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.10.025

文献信息

• [EN] SUBSTITUTED GEMCITABINE BICYCLIC AMIDE ANALOGS AND TREATMENT METHODS USING SAME<br/>[FR] ANALOGUES D'AMIDE BICYCLIQUE DE GEMCITABINE SUBSTITUÉS ET MÉTHODES DE TRAITEMENT À L'AIDE DE CEUX-CI
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2014145207A1

  公开（公告）日：2014-09-18

  In one aspect, the invention relates to substituted gemcitabine aryl amide analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating viral disorders and disorders of uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及替代吉西他滨芳基酰胺类似物，其衍生物和相关化合物；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗病毒性疾病和细胞不受控制增殖的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不意味着对本发明的限制。
• Phenolic Esters of O-Desmethylvenlafaxine with Improved Oral Bioavailability and Brain Uptake
  作者：Yang Zhang、Yan Yang、Sen Zhao、Zhichao Yang、Hong Yang、J. Paul Fawcett、Youxin Li、Jingkai Gu、Tiemin Sun

  DOI：10.3390/molecules181214920

  日期：——

  O-Desmethylvenlafaxine (desvenlafaxine, ODV) is a recently approved antidepressant which in some clinical studies failed to meet a satisfactory end-point. The aim of this study was to prepare a series of phenolic esters of ODV and evaluate their potential as ODV prodrugs with improved brain uptake. Fifteen phenolic esters (compounds 1a–o) were synthesized and their pharmacokinetic profiles evaluated in rat. The four compounds producing the highest relative bioavailability of ODV in rat (compounds 1c, 1e, 1n, 1o) were then studied to evaluate their brain uptake. Of these four compounds, compound 1n (the piperonylic acid ester of ODV) demonstrated the highest Cmax of ODV both in the rat hypothalamus and total brain. Finally the pharmacokinetics of 1n were evaluated in beagle dog where the increase in relative bioavailability of ODV was found to be as great as in rat. This high relative bioavailability of ODV coupled with its good brain penetration make 1n the most promising candidate for development as an ODV prodrug.

  O-去甲文拉法辛（去文拉法辛，ODV）是一种新近批准的抗抑郁药，在一些临床研究中未能达到令人满意的治疗终点。本研究旨在制备一系列ODV的酚酯类化合物，并评估它们作为脑摄取改善的ODV前药的潜力。合成了十五种酚酯类化合物（化合物1a-o），并在大鼠中评估了它们的药代动力学特征。然后对在大鼠中产生最高相对生物利用度的四种化合物（化合物1c、1e、1n、1o）进行了研究，以评估它们的脑摄取情况。在这四种化合物中，化合物1n（ODV的胡椒酸酯）在大鼠下丘脑和全脑中均显示出最高的ODV峰浓度。最后，在比格犬中评估了化合物1n的药代动力学特征，结果发现其ODV相对生物利用度的增加与大鼠中相当。这种高相对生物利用度以及良好的脑渗透性使得化合物1n成为最有希望开发为ODV前药的候选化合物。
• Decarbonylative Cyanation of Amides by Palladium Catalysis
  作者：Shicheng Shi、Michal Szostak

  DOI：10.1021/acs.orglett.7b01199

  日期：2017.6.16

  Transition-metal-catalyzed cyanation of aryl halides is a process of significant importance in the preparation pharmaceuticals, organic materials and agrochemicals. Here, we demonstrate a palladium-catalyzed decarbonylative cyanation of amides by highly selective carbon–nitrogen bond cleavage for the synthesis of a wide range of aryl nitriles. The utility of this technology is demonstrated by the synthesis

  过渡金属催化的芳基卤化物氰化是制备药物，有机材料和农药的重要过程。在这里，我们通过高选择性的碳-氮键裂解展示了钯催化的酰胺的脱羰氰化氰化物，用于合成各种芳基腈。同位素标记的芳基腈的合成和稳固酰胺的正交交叉偶联反应可建立具有相反极性的交叉偶联合成子，从而证明了该技术的实用性。
• Synthesis of 2-Substituted Propenes by Bidentate Phosphine-Assisted Methylenation of Acyl Fluorides and Acyl Chlorides with AlMe₃
  作者：Xiu Wang、Zhenhua Wang、Yuya Asanuma、Yasushi Nishihara

  DOI：10.1021/acs.orglett.9b01059

  日期：2019.5.17

  methylenation of acyl fluorides and acyl chlorides with substituted with aryl, alkenyl, and alkyl groups trimethylaluminum afforded an array of 2-substituted propene derivatives. The addition of a catalytic amount of DPPM increased an efficiency of the reactions. Trimethylaluminum as the methylenation reagent not only eliminates the presynthesis of methylene transfer reagent, but provides an efficient method for

  芳基，烯基和烷基三甲基铝取代的酰氟和酰氯的双膦膦化亚甲基化提供了一系列2取代的丙烯衍生物。催化量的DPPM的添加提高了反应效率。三甲基铝作为亚甲基化试剂，不仅消除了亚甲基转移试剂的预合成，而且为合成一系列2-取代的丙烯提供了一种有效的方法。
• Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities
  作者：Qinghui Wang、Kinsie E. Arnst、Yuxi Wang、Gyanendra Kumar、Dejian Ma、Hao Chen、Zhongzhi Wu、Jinliang Yang、Stephen W. White、Duane D. Miller、Wei Li

  DOI：10.1021/acs.jmedchem.8b00827

  日期：2018.9.13

  Colchicine binding site inhibitors (CBSIs) hold great potential in developing new generations of antimitotic drugs. Unlike existing tubulin inhibitors such as paclitaxel, they are generally much less susceptible to resistance caused by the overexpression of drug efflux pumps. The 3,4,5-trimethoxyphenyl (TMP) moiety is a critical component present in many CBSIs, playing an important role in maintaining

  秋水仙碱结合位点抑制剂（CBSI）在开发新一代抗有丝分裂药物方面具有巨大潜力。与现有的微管蛋白抑制剂（例如紫杉醇）不同，它们通常不易受到药物外排泵过表达引起的耐药性的影响。3,4,5-三甲氧基苯基（TMP）部分是许多CBSI中存在的关键组分，在维持CBSI的合适分子构象并促进其与微管蛋白的高结合亲和力中起重要作用。先前报道的各种CBSI支架中TMP部分的修饰通常导致抗增殖能力降低。我们之前曾报道过一种有效的CBSI，即VERU-111，它也含有TMP部分。在此，我们报告发现VERU-111类似物13f比VERU-111更有力。与微管蛋白复合的13f的X射线晶体结构证实了其与秋水仙碱位点的直接结合。另外，13f在体内对肿瘤生长表现出强烈的抑制作用。